Dosimetry-Based Consideration on Remission and Relapse After Therapy with Ra-Dichloride in Castration-Resistant Prostate Cancer (CRPC) with Bone Metastases. A Case Report

Overview

Journal Diagnostics (Basel)

Specialty Radiology

Date 2018 Mar 3

PMID 29495541

Citations 1

Authors

Anna Maria Mangano

Massimiliano Pacilio

Pasquale Ialongo

Alessandro Semprebene

Guido Ventroni

Lucio Mango

Affiliations

Soon will be listed here.

Abstract

Here, we present the case of a 64-year-old male patient diagnosed with castration-resistant prostate cancer (CRPC) with bone metastasis, treated with abiraterone prednisone/prednisolone in combination with Ra-dichloride therapy, who had remission and a subsequent relapse of bone metastasis on repeated bone scans after therapy. We also discuss the possibility of continuing the Ra-dichloride therapy over the six planned administrations by administering other cycles at the same dose or at higher doses, if shown to be devoid of a significant increase in side effects, based on dosimetry considerations.

Citing Articles

The homogeneous and heterogeneous risk factors for the morbidity and prognosis of bone metastasis in patients with prostate cancer.

Guo X, Zhang C, Guo Q, Xu Y, Feng G, Li L Cancer Manag Res. 2018; 10:1639-1646.

PMID: 29970963 PMC: 6021002. DOI: 10.2147/CMAR.S168579.

References

Pacilio M, Ventroni G, Cassano B, Ialongo P, Lorenzon L, Di Castro E . A case report of image-based dosimetry of bone metastases with Alpharadin ((223)Ra-dichloride) therapy: inter-fraction variability of absorbed dose and follow-up. Ann Nucl Med. 2015; 30(2):163-8. DOI: 10.1007/s12149-015-1044-9. View

Henriksen G, Breistol K, Bruland O, Fodstad O, Larsen R . Significant antitumor effect from bone-seeking, alpha-particle-emitting (223)Ra demonstrated in an experimental skeletal metastases model. Cancer Res. 2002; 62(11):3120-5. View

Hobbs R, Song H, Watchman C, Bolch W, Aksnes A, Ramdahl T . A bone marrow toxicity model for ²²³Ra alpha-emitter radiopharmaceutical therapy. Phys Med Biol. 2012; 57(10):3207-22. PMC: 3442928. DOI: 10.1088/0031-9155/57/10/3207. View

Estorch Cabrera M, Rey P, Carrio I, Montes A, Lopez D . Response to Ra-dichloride in castration-resistant prostate cancer with bone metastasis: A case report. Oncol Lett. 2016; 12(2):1323-1328. PMC: 4950721. DOI: 10.3892/ol.2016.4762. View

Nilsson S, Larsen R, Fossa S, Balteskard L, Borch K, Westlin J . First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases. Clin Cancer Res. 2005; 11(12):4451-9. DOI: 10.1158/1078-0432.CCR-04-2244. View

Herranz U, Fernandez Calvo O, Afonso Afonso F, Rodriguez Martinez de Llano S, Lazaro Quintela M, Leon Mateos L . Radium-223 dichloride: a new paradigm in the treatment of prostate cancer. Expert Rev Anticancer Ther. 2015; 15(3):339-48. DOI: 10.1586/14737140.2015.999045. View

Nilsson S, Strang P, Aksnes A, Franzen L, Olivier P, Pecking A . A randomized, dose-response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer. Eur J Cancer. 2012; 48(5):678-86. DOI: 10.1016/j.ejca.2011.12.023. View

Pandit-Taskar N, Larson S, Carrasquillo J . Bone-seeking radiopharmaceuticals for treatment of osseous metastases, Part 1: α therapy with 223Ra-dichloride. J Nucl Med. 2013; 55(2):268-74. DOI: 10.2967/jnumed.112.112482. View

Nilsson S, Franzen L, Parker C, Tyrrell C, Blom R, Tennvall J . Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study. Lancet Oncol. 2007; 8(7):587-94. DOI: 10.1016/S1470-2045(07)70147-X. View

10.

Flux G . Imaging and dosimetry for radium-223: the potential for personalized treatment. Br J Radiol. 2017; 90(1077):20160748. PMC: 5858794. DOI: 10.1259/bjr.20160748. View

11.

Sartor O, Coleman R, Nilsson S, Heinrich D, Helle S, OSullivan J . Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial. Lancet Oncol. 2014; 15(7):738-46. DOI: 10.1016/S1470-2045(14)70183-4. View

12.

Jadvar H, Quinn D . Targeted α-particle therapy of bone metastases in prostate cancer. Clin Nucl Med. 2013; 38(12):966-71. PMC: 3874447. DOI: 10.1097/RLU.0000000000000290. View

13.

Roeske J, McDevitt M, Palm S, Allen B, Song H, Akabani G . MIRD Pamphlet No. 22 (abridged): radiobiology and dosimetry of alpha-particle emitters for targeted radionuclide therapy. J Nucl Med. 2010; 51(2):311-28. PMC: 5680544. DOI: 10.2967/jnumed.108.058651. View

14.

Coleman R . Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res. 2006; 12(20 Pt 2):6243s-6249s. DOI: 10.1158/1078-0432.CCR-06-0931. View

15.

Hamdy N, Papapoulos S . The palliative management of skeletal metastases in prostate cancer: use of bone-seeking radionuclides and bisphosphonates. Semin Nucl Med. 2001; 31(1):62-8. DOI: 10.1053/snuc.2001.18767. View

16.

Florimonte L, Dellavedova L, Maffioli L . Radium-223 dichloride in clinical practice: a review. Eur J Nucl Med Mol Imaging. 2016; 43(10):1896-909. DOI: 10.1007/s00259-016-3386-5. View

17.

Pacilio M, Ventroni G, De Vincentis G, Cassano B, Pellegrini R, Di Castro E . Dosimetry of bone metastases in targeted radionuclide therapy with alpha-emitting (223)Ra-dichloride. Eur J Nucl Med Mol Imaging. 2015; 43(1):21-33. DOI: 10.1007/s00259-015-3150-2. View

18.

Murray I, Chittenden S, Denis-Bacelar A, Hindorf C, Parker C, Chua S . The potential of Ra and F-fluoride imaging to predict bone lesion response to treatment with Ra-dichloride in castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2017; 44(11):1832-1844. PMC: 6175045. DOI: 10.1007/s00259-017-3744-y. View

19.

Humphrey P . Gleason grading and prognostic factors in carcinoma of the prostate. Mod Pathol. 2004; 17(3):292-306. DOI: 10.1038/modpathol.3800054. View

20.

Lewington V . Bone-seeking radionuclides for therapy. J Nucl Med. 2005; 46 Suppl 1:38S-47S. View